ym biosciences corporate presentatoion

1 YM Corporate Presentation | Calendar Q2/2012

BioFinance PresentationCalendar Q2 2012


Safe Harbor

This presentation may contain forward-looking statements, which reflect the Company's current

expectation regarding future events. These forward-looking statements involve risks and uncertainties that

may cause actual results, events or developments to be materially different from any future results, events

or developments expressed or implied by such forward-looking statements. Such factors include, but are

not limited to, changing market conditions, the successful and timely completion of clinical studies, the

establishment of corporate alliances, the impact of competitive products and pricing, new product

development, uncertainties related to the regulatory approval process or the ability to obtain drug product

in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or

to meet commercial demand, and other risks detailed from time to time in the Company's ongoing

quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements

include but are not limited to the following: that our JAK1/JAK2 inhibitor CYT387, nimotuzumab and our

VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials, and that

YM and its various partners will complete their respective clinical trials within the timelines communicated.

Except as required by applicable securities laws, we undertake no obligation to publicly update or revise

any forward-looking statements, whether as a result of new information, future events or otherwise.


Corporate Information

Net Cash (Mar 31, 2012) $137.2mm

Cash used in last 12 months (Dec 31, 2011) $26.7mm

Market cap (May 8, 2012) $282mm

Volume (3-month average) ~1.1mm shares/day

Total shares outstanding (Mar 31, 2012) 157.4mm

Warrants @ $1.60 (to Mar 10, 2015) 7.4mm

Options1 (Mar 31, 2012) 8.2mm

No debt or preferred shares1 Weighted average exercise price $1.92


Analyst Coverage

Firm AnalystBank of America Merrill Lynch Rachel McMinnBloom Burton & Co. Philippa FlintByron Capital Markets Ltd. Doug LoeCanaccord Genuity Salveen RichterEdison Investment Research Jacob PliethGriffin Securities Chrystyna BedrijJMP Securities Liisa BaykoParadigm Capital Alan RidgewayPiper Jaffray M. Ian SomaiyaRodman & Renshaw Reni BenjaminROTH Capital Partners Joseph PantginisWells Fargo Securities Brian Abrahams


YM BioSciences

1 Weighted average exercise price $1.99

Product Preclinical Phase I Phase II Phase III

CYT387JAK1/JAK2 inhibitorPositive interim Phase I/II myelofibrosis data presented at ASH 2011

NimotuzumabEGFR targeting antibodyMultiple Phase II and Phase III trials

CYT997Tubulin inhibitorIV + oral formulation development

Kinase Inhibitor Library~4000 molecules including JAK RA candidates


Our Significant Expertise in JAK Research

YM acquired original intellectual assets in JAK field

– Lead product CYT387

– Wholly-owned and un-partnered

– First group to publish crystal structures of JAK2 and JAK1

– Medicinal chemistry and molecular modeling expertise

– Novartis collaboration for selective JAK3 inhibitors

Intellectual Property

CYT387 Composition of MatterUS: Pending, 2028 expiryEU: Pending, 2028 expiry

JAK2 Crystal StructureUS: Issued, 2025 expiryEU: Pending, 2026 expiry

JAK2 EnzymeUS: Issued, 2015 expiryEU: Issued, 2011 expiry


Target Markets for JAK Inhibitors

Cancer / Hematology

Autoimmune Diseases

– RheumatoidArthritis

– Psoriasis

– Graft vs. HostDisease

Myeloproliferative Neoplasms

– Myelofibrosis

– Polycythemia Vera

– Essential Thrombocythemia

– Leukemia and Lymphoa

– Solid Tumors

– Other Hematologic Disorders

Chronic Disorders Clinical Proof of Concept Acute Diseases


Industry Enthusiasm for JAK Inhibitors

Oncology / Hematology Inflammatory Diseases

Novartis / Incyte– Jakafi™ approved for myelofibrosis– Partnered (2009) for $150mm upfront ($1bn

total) for Ex-US rights

Pfizer– Tofacitinib in Phase III in rheumatoid

arthritis– Peak sales projection: $2-3B

Sanofi Aventis– SAR302503 starting Phase III in myelofibrosis– Acquired TargeGen 2010) for $75mm upfront

($560mm total)

Lilly / Incyte– INCB28050 in Phase III in rheumatoid

arthritis– Partnered (2009) for $90mm upfront

($665mm total) for Worldwide rights

S*BIO / Cell Therapeutics– Pancritinib starting Phase III in myelofibrosis– Partnered with Onyx (2009) (subsequently

returned) for $25mm upfront ($550mm total) for US, Europe rights

– Partnered with CTI (2012) for $30mm upfront

Abbott / Galapagos– GLPG0634 in Phase II in rheumatoid

arthritis– Partnered (2012) for $150mm upfront

($1.6bn total) for Worldwide rights


Myelofibrosis: Initial Indication for CYT387

– Decreased erythropoiesis or thrombopoiesis

– Proliferation of dysfunctional megakaryocytes

– Hypercellular bone marrow leading to fibrosis

– Extramedullary hematopoiesis

– Elevated cytokine levels

– Anemia – often requiring transfusions

– Thrombocytopenia

– Splenomegaly

– Constitutional symptomsFatigue, night sweats, pruritus, bone pain, weight loss, fever


Anemia Impacts Survival in Myelofibrosis

– ~70% of myelofibrosis patients are Intermediate-II or High risk †

– Estimated that 30-50% of all myelofibrosis patient are transfusion dependent‡, majority of which are Intermediate-II and High risk patients

† DIPSS-Plus; Gangat et al. JCO 2011; 29(4), 392‡ Elena et al. Haematologica 2011 96(1) 167

Anemia at any timeAnemia at diagnosis


CYT387: Target Product Profile

CYT387 is able to provide a clinically meaningful benefit to myelofibrosis patients by:

… while having a significantly lower risk of causing or worsening hematological adverse events such as thrombocytopenia, anemia and neutropenia.

1. Converting transfusion dependent patients to transfusion independent status

2. Reducing spleen volume in patients with enlarged spleens

3. Improving constitutional symptoms and quality of life


Current Study Status: ASH 2011

Initiated Nov 2009 Initiated Aug 2010 Initiated Dec 2010

100 mg QD (n=3)150 mg QD (n=3)200 mg QD (n=3)300 mg QD (n=6)400 mg QD (n=6)

150 mg QD (n=18)300 mg QD (n=21)

150 mg QD (n = 31)300 mg QD (n = 33)150 mg BID (n = 42)

DLT level: 400 mg QD MTD: 300 mg QD

Mayo Clinic (Rochester, Minnesota)Dana Farber Cancer Institute (Boston)Stanford Cancer Center (Stanford)Royal Melbourne Hospital (Melbourne)Princess Margaret Hospital (Toronto)Jewish General Hospital (Montreal)

Mayo Clinic Mayo Clinic

– Enrollment complete– Data collection and

analysis ongoing– 97% of patients

entered the Extension phase as at ASH 2011

Dose Escalation

Phase (n = 21)

Dose Confirmation

Phase (n = 39)

Dose Expansion

Phase (n = 106)

Dose Extension

Study (n = 104)

166 Patient Phase I/II Study


Maximum Duration of Transfusion-Free Period*

0 100 200 300 400 500

Time (days)

Res

pond

ers

* To date

Clinically relevant maintenance of transfusion independence period


Maximal Change in Palpable Spleen Size*

* Ongoing

-100%

-80%

-60%

-40%

-20%

0%

20%

40%

60%

80%

% C

hang

e Fr

om B

asel

ine

(Core Study; n=142)

≥ 25% decrease from baseline: 87%≥ 50% decrease from baseline: 49%≥ 75% decrease from baseline: 25%100% decrease from baseline: 16%


Constitutional Symptoms Response at Six Months

23% 22% 23%19%

11%

57%52%

44%

30%

89%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Night Sweats(n=62)

Pruritis(n=46)

Bone Pain(n=43)

Cough(n=27)

Fever(n=9)

Perc

enta

ge o

f Pat

ient

s

Complete Resolution

Marked Improvement

Complete resolution or marked improvement of common constitutional symptoms is achieved in the majority of subjects


Reported Adverse Events

Adverse Event (n=166) All Grades Grade 3 Grade 4

ThrombocytopeniaBaseline platelets > 100 x 109/LBaseline platelets > 200 x 109/L

33%26%12%

11%6%4%

6%2%0

Neutropenia 6% 1% 2%

Anemia 4% 1% 0

Leukopenia 2% <1% <1%

Leukocytosis 1% <1% 0

At least possibly related to study drugCommon Terminology Criteria for Adverse Events v3.0

Reported adverse effects include thrombocytopenia; transient, mild dizziness; mild peripheral neuropathy; and abnormalities in liver/pancreas-related laboratory tests

Treatment-emergent anemia and neutropenia are rare


Variable Diagnosis* >1 year* CYT387

Anemia 38% 64% Benefit

Transfusion dependency 25% 45% Benefit

Palpable spleen >10cm 21% 46% Benefit

Constitutional symptoms 29% 34% Benefit

CYT387 Well Suited for Myelofibrosis

CYT387 has a profile that addresses MF clinical needs and overarching risk factors

> Benefit on anemia and transfusion dependency> Activity for spleen and symptoms> Lower myelosuppression

CYT387 is well tolerated for dosing periods up to and exceeding two years

* Mayo Clin Proc 2012;87(1): 25-33


CYT387 Myelofibrosis Development Pathway

Dec 2010Interim data

at ASH

Q2 2011Interim data

at ASCO

Q3 2011Completedenrollment

Q4 2011Multicenter data at ASH

166-patient Phase I/II

Q3 2011Initiated enrollment

Q4 2012Report data

~60 patient Phase II BID

Q4 2012Report final core

study data & extension study

data

Pivotal program

H2 2012Initiate enrollment

Extension study


CYT387 Development and Commercial Opportunities

Myeloproliferative Neoplasms

Clinical proof-of-concept

Speed to market strategy

Expand hematological

indications/franchise

Hematological Disorders

Market expansion

Lifecycle management

Solid Tumors

– Myelodysplastic Syndromes (MDS)

– Multiple Myeloma

– Leukemias (AML, CML…)

– Lymphomas (NHL…)

– Myelofibrosis

– PV

– ET

– Orphan MPNs

– Prostate cancer

– Hepatocellular

– NSCLC

– Gastric

– Colorectal

– Etc.


CYT387 – Safe, Effective, Differentiated

– Focused on emerging JAK therapeutic class with broad market potential

– Potential ‘Best-in-Class’ profile

– Established safety and efficacy

– Wholly owned and un-partnered

– Well capitalized

ym biosciences corporate presentatoion

Business